ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
7.98
+0.05 (0.63%)
At close: May 29, 2026, 4:00 PM EDT
8.04
+0.06 (0.73%)
After-hours: May 29, 2026, 7:59 PM EDT
ADMA Biologics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 509.86 | 510.17 | 426.45 | 258.22 | 154.08 | 80.94 | |
Revenue Growth (YoY) | 10.99% | 19.63% | 65.16% | 67.58% | 90.36% | 91.72% |
Cost of Revenue | 197.45 | 217.41 | 206.9 | 169.27 | 118.82 | 79.77 |
Gross Profit | 312.42 | 292.77 | 219.55 | 88.94 | 35.27 | 1.17 |
Selling, General & Admin | 94.24 | 91.58 | 74.12 | 59.02 | 52.46 | 42.9 |
Depreciation & Amortization Expenses | 0.18 | 0.14 | 0.39 | 0.72 | 0.72 | 0.72 |
Research & Development | 6.53 | 4.76 | 1.81 | 3.3 | 3.61 | 3.65 |
Other Operating Expenses | 12.59 | 4.84 | 4.25 | 4.27 | 17.84 | 12.29 |
Total Operating Expenses | 113.54 | 101.32 | 80.57 | 67.31 | 74.63 | 59.55 |
Operating Income | 214.84 | 191.44 | 138.98 | 21.63 | -39.37 | -58.37 |
Interest Income | 2.36 | 1.87 | 2.1 | 1.62 | 0.05 | 0.04 |
Interest Expense | -7.24 | -7.11 | -13.93 | -25.03 | -19.28 | -13.06 |
Other Non-Operating Income (Expense) | -12.12 | -12.34 | -14.71 | -76.33 | -33.84 | -13.53 |
Total Non-Operating Income (Expense) | -17 | -17.57 | -26.54 | -99.74 | -53.08 | -26.55 |
Pretax Income | 206.33 | 182.66 | 125.71 | -28.24 | -65.9 | -84.92 |
Provision for Income Taxes | 40.98 | 35.73 | -71.96 | - | - | - |
Net Income | 165.35 | 146.93 | 197.67 | -28.24 | -65.9 | -71.65 |
Net Income to Common | 165.35 | 146.93 | 197.67 | -28.24 | -65.9 | -71.65 |
Net Income Growth | -20.03% | -25.67% | - | - | - | - |
Shares Outstanding (Basic) | 239 | 238 | 233 | 224 | 198 | 140 |
Shares Outstanding (Diluted) | 244 | 245 | 243 | 224 | 198 | 140 |
Shares Change (YoY) | -0.05% | 0.64% | 8.65% | 13.19% | 41.77% | 62.03% |
EPS (Basic) | 0.69 | 0.62 | 0.85 | -0.13 | -0.33 | -0.51 |
EPS (Diluted) | 0.68 | 0.60 | 0.81 | -0.13 | -0.33 | -0.51 |
EPS Growth | -20.00% | -25.93% | - | - | - | - |
Shares Outstanding | 232.29 | 237.87 | 236.62 | 226.06 | 221.82 | 195.81 |
Free Cash Flow | 107.9 | 27.82 | 110.45 | 4.03 | -73.42 | -125.88 |
Free Cash Flow Growth | 287.85% | -74.81% | 2641.28% | - | - | - |
Free Cash Flow Per Share | 0.44 | 0.11 | 0.45 | 0.02 | -0.37 | -0.90 |
Gross Margin | 61.27% | 57.39% | 51.48% | 34.44% | 22.89% | 1.45% |
Operating Margin | 42.14% | 37.53% | 32.59% | 8.38% | -25.55% | -72.12% |
Profit Margin | 32.43% | 28.80% | 46.35% | -10.94% | -42.77% | -104.92% |
FCF Margin | 21.16% | 5.45% | 25.90% | 1.56% | -47.65% | -155.52% |
EBITDA | 222.8 | 199.54 | 147.03 | 29.96 | -32.25 | -52.88 |
EBITDA Margin | 43.70% | 39.11% | 34.48% | 11.60% | -20.93% | -65.33% |
EBIT | 214.84 | 191.44 | 138.98 | 21.63 | -39.37 | -58.37 |
EBIT Margin | 42.14% | 37.53% | 32.59% | 8.38% | -25.55% | -72.12% |
Effective Tax Rate | 19.86% | 19.56% | -57.24% | 0.00% | 0.00% | 0.00% |